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Moderate amplifications of the comyc gene correlate
with molecular and clinicopathological parameters in
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Summary C-mycgene activation is a common event in multiple types of neoplasia and has been associated with different cellular processes
relevant to the malignant transformation of cancer cells. C-myc gene amplification has been analysed in colorectal carcinomas by means of
an innovative DNA fingerprinting method based on the arbitrarily primed PCR. This method requires a low amount of DNA, uses multiple
internal controls and appears sensitive and reproducible. Clinicopathological and molecular correlates have been investigated in a series of
70 colorectal carcinomas. The incidence of c-myc amplification was 26%, ranging from two- to fivefold increase in copy number. C-myc
amplification occurrence was more frequent in more advanced stages of tumour invasion (P < 0.001) and was associated with mutations in
the p53tumour-suppressor gene (P = 0.048). The presence of c-mycamplification was indicative of a shorter disease-free survival period but,
because of its strong association with Dukes' stage, its prognostic value is questionable.
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After the initial finding ofan amplified c-myc gene (also known as
MYC) in different human cell lines (Collins and Groudine, 1982;
Alitalo et al, 1983; Little et al, 1983), oncogenic activation of the
c-myc gene through amplification has been demonstrated in
multiple types ofcancer (reviewed by Bishop, 1991; Garte, 1993).
Previous studies have shown that c-myc gene amplification and/or
overexpression in colorectal cancer correlates with the degree of
invasion (Kozma et al, 1994; Sato et al, 1994) and poor differenti-
ation (Heerdt et al, 1991). Nevertheless, other authors have failed
to find such associations (Erisman et al, 1988; Finley et al, 1989;
Matsumara et al, 1990; Nagai et al, 1992; Smith et al, 1993).
Although c-myc overexpression appears in an elevated proportion
oftumours (66-90%) (Erisman et al, 1985; 1988; Matsumara et al,
1990; Smith et al, 1993; Sato et al, 1994; Wang et al, 1994), gene
amplification, as determined by Southern (Erisman et al, 1985;
Untawale and Blick, 1988; Finley et al, 1989; Matsumara et al,
1990; Heerdt et al, 1991) or dot-blot hybridization (Erisman et al,
1988; Nagai et al, 1992; Smith et al, 1993; Kozma et al, 1994;
Wang et al, 1994) is less frequent, ranging from 0 to 30%. In
addition to the intrinsic complexity of cellular processes, sample
heterogeneity and methodological pitfalls are important factors
that puzzle the comprehensibility ofthese divergences.
With the advent of the polymerase chain reaction (PCR) and in
order to overcome the limitation of blot hybridization techniques
(mainly, a high amount of genomic DNA is required), different
quantitative PCR methods for c-myc analysis have been developed
(Rhoer-Moja et al, 1993; Watson et al, 1993; Sugimoto et al, 1994;
Sestini et al, 1995). PCR co-amplification of the c-myc gene with
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an internal control did not render reliable results in our hands.
Theoretical and practical considerations limit the accuracy of this
type of technique, often generating irreproducible results (see
review by Ferre et al, 1994).
The initial aim of this study was to determine the possible rela-
tionship between c-myc gene amplification and molecular and
clinicopathological variables in a series of colorectal carcinomas.
As only a limited amount of DNA was available from normal and
tumour tissue (making the use of hybridization-type methods
impossible) and in order to overcome the technical limitations
described above, we have set up a PCR-derived method that uses
multiple internal and arbitrary controls. This technique is based on
the arbitrarily primed PCR (AP-PCR) (Welsh and McClelland,
1990), a fingerprinting-type technique using primers whose
nucleotide sequence is arbitrarily chosen.
It has been demonstrated that AP-PCR is useful for the detec-
tion and isolation of tumour-specific allelic losses and gains
(Peinado et al, 1992; Kohno et al, 1994; Achille et al, 1996), thus
providing a molecular alternative to cancer cytogenetics. In addi-
tion, DNA fingerprinting by AP-PCR permitted the discovery of
ubiquitous somatic genomic instability in a subset of colorectal
tumours (Ionov et al, 1993). More recently, AP-PCR finger-
printing has been used to estimate the degree of genomic damage
in colorectal tumours (Bocker et al, 1996; Arribas et al, 1997;
Basik et al, 1997). We have observed that the rate of genomic
damage in neoplastic cells, as determined by AP-PCR, may have
important prognostic applications (Arribas et al, 1997). Two
intrinsic features of AP-PCR are of special interest: (a) the ampli-
fied sequences proceed from randomly selected genome regions
with no apparent bias for the chromosomal origin of the bands
(Peinado et al, 1992; Yasuda et al, 1996); and (b) the amplification
is quantitative in that the intensity of an amplified band is propor-
tional to the concentration of its corresponding template sequence
(Peinado et al, 1992; Perucho et al, 1995).
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In our approach, primers are designed to amplify a fragment
including the third exon of the human c-myc gene and PCR is
performed under low-stringency conditions, as in AP-PCR. In
consequence, the c-myc gene fragment is co-amplified with a
number of arbitrary sequences that consistently appear in all the
samples. These sequences are flanked by the same primers as the
c-myc gene and competition among them generates a quantitative
fingerprint (see scheme in Figure 1). Furthermore, we can expect
Table 1 Molecular and clinical data of patients classified by the Dukes' stagea
Stage Case Age Sex DFS Rec Follow-up (months) Dead p53 ras MMP c-myc
Dukes
A
Dukes
B
Dukes
C
Dukes
D
6
44
51
57
58
60
66
83
89
119
135
180
33
36
42
45
47
48
49
55
59
62
68
78
91
100
118
121
132
136
150
153
188
190
193
27
56
94
96
101
117
134
137
156
189
191
192
201
202
213
65
80
125
133
182
197
268
77
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67
71
69
75
76
73
39
61
79
55
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80
77
76
59
81
60
68
56
62
73
62
53
60
70
66
71
58
69
63
56
63
68
63
76
56
66
61
93
62
71
60
71
78
64
54
53
48
64
57
56
47
69
57
77
M
F
F
M
M
F
F
M
M
M
F
M
M
F
M
M
M
M
M
M
M
M
M
M
F
F
M
F
M
M
M
M
M
M
F
M
M
M
M
M
M
F
M
M
F
M
M
F
M
M
M
M
F
M
F
M
M
62
96
68
83
78
43
44
52
84
60
65
81
29
27
85
84
87
31
62
84
70
79
34
71
28
61
61
45
59
19
15
49
44
68
48
5
84
67
20
61
9
66
29
30
6
3
78
76
69
22
52
9
12
21
36
5
5
Yes
No
Yes
No
No
No
Yes
No
No
No
No
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
No
No
Yes
No
Yes
Yes
No
Yes
No
No
Yes
No
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
94
96
68
83
78
43
80
52
84
60
65
81
29
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85
84
87
31
84
84
70
79
34
71
28
61
61
45
59
19
15
49
46
68
48
5
84
67
20
61
9
66
29
57
6
3
78
76
69
22
52
9
12
21
36
5
5
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
No
No
No
Yes
Yes
No
No
No
No
No
No
No
No
Yes
No
Yes
Yes
No
Yes
No
No
Yes
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
No
Yes
ND
ND
+
+
ND
+
+
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aOnly cases with available follow-up data are included. Sex: M, male, F, female; DFS, disease-free survival in months; Rec, recurrent disease; Dead: Yes, died
of disease; No, alive with or without disease, dead of unrelated causes; p53and ras: +, with mutation; - no mutation; ND, not determined; MMP, microsatellite
mutator phenotype: +, instability in at least two out of five microsatellites sequences; -, no instability; c-myc; +, gene amplification; -, no gene amplification.
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that these sequences are of different chromosomal origin and, in
consequence, they are useful as internal controls. As the rationale
of this technique is based on the properties of AP-PCR, we have
called this method targeted AP-PCR (TAP-PCR).
We have applied TAP-PCR to the allelic dosage of the c-mvc
gene in a series ofcolorectal tumours of which a limited amount of
DNA was available. We have observed moderate c-myc gene ampli-
fications in about one-quarter ofthe tumours. Amplifications ofthe
c-mvc gene occurred more frequently in advanced stages oftumour
invasion and were associated with mutations in thep53 gene.
MATERIAL AND METHODS
Samples
Seventy colorectal carcinomas and paired normal tissue samples
were obtained from the Human Tissue Cooperative Network
(University of Alabama, Birmingham, USA). Phenotypic and
genetic characteristics of these cases have been described else-
where as part of a larger series (Capella et al, 1991; Peinado et al,
1993). The samples used in this study were selected from a collec-
tion of 181 cases based on availability of genomic DNA from
tumour and paired normal mucosa. They were representative of
the whole collection for all the molecular and clinicopathological
parameters considered. Cases were pathologically staged using
Astler-Coller modification of Dukes' classification system.
Detailed histological study of a short series of cases revealed that
in most cases (16 out of 17) more than 75% ofthe analysed tissue
was composed of neoplastic cells. In a single case, stromal and
normal epithelial cells constituted approximately 50% of the
tissue. SW480 and DLD-1 cell lines (ATCC, Rockville, MD,
USA) were used as positive and negative controls, respectively, for
c-mvc amplification. Cases with perioperative deaths and with
insufficient follow-up were excluded from the survival analysis.
Molecular analyses
Genomic DNA was extracted by the phenol-chloroform method as
described previously (Nakano et al, 1984). DNA was diluted to a
concentration of 20 ng gl-l and 1 gl of each DNA was run in a
A
TargetedarbNradlypnrmedPCR
(TAP-PCR)
0.75% agarose gel and stained with ethidium bromide to verify its
quality and concentration. When necessary, the DNA concentra-
tion was adjusted according to the ethidium bromide signal.
Mutations at codons 12 and 13 ofthe K-ras gene and 12 ofthe N-
ras gene were detected and characterized by the artifical RFLP/PCR
approach (Capella et al, 1991). p53 mutations in exons 4-9 were
analysed using single-strand conformation polymorphism (SSCP) of
PCR amplified products and characterized by direct cycle
sequencing of the PCR product (Peinado et al, 1993). Genomic
instability at simple repeated sequences was analysed in microsatel-
lite sequences AP2, AP3, Mfd27, Mfd41 and Mfd47 as described
previously (Ionov et al, 1993; Shibata et al, 1994). Cases showing
instability in two or more microsatellites were considered to belong
to the microsatellite mutator phenotype (MMP) pathway. In agree-
ment with other reports (Thibodeau et al, 1993), tumours with low
genomic instability (mutations in only one out offive microsatellite
sequences analysed) present molecular and biological characteris-
tics different from those with high instability but similar to the rest.
In consequence, they were considered MMP negative.
TAP-PCR of c-myc
TAP-PCR reactions were performed in duplicate with 50ng of
genomic DNA, 125 gM each dNTP, 1 gM each primer (sense:
5'-AAAGAGGCAGGCTCCTGGCA-3', antisense: 5'-TCTCGTC-
GTFFTCGCAACAA-3'), 1 gCi [x-33P]dATP (Amersham,
Buckinghamshire, UK) and 1.25 units of Taq polymerase
(Boehringer Mannheim, Mannheim, Germany) in PCR buffer
(10 mm Tris-HCl pH 8.0, 50 mm potassium chloride, 1.5 mm magne-
sium chloride) in a final volume of 25 gl. The reaction consisted of
five low-stringency cycles (30 s at 94°C, 30 s at 50°C, 30 s at 72°C)
and 35 high-stringency cycles (30 s at 94°C, 30 s at 65°C, 30 s at
72°C) and was carried out in a PTC-100 thermocycler (MJ Research,
Watertown, MA, USA). The product was diluted with formamide
dye buffer, denatured for 3 min at 95°C and 3 ,ul were run on a 6%
acrylamide 8 M urea sequencing gel at 55 W for 3 h. The gels were
dried under vacuum at 85°C and exposed to radiograph film at room
temperature without intensifier screen for 1-3 days. The amplified
c-myc region corresponds to afragment 470-bp-long, which includes
A R C
B
46- ~ ~ ~ ~-
Figure 1 Principles of TAP-PCR method. Conventional PCR amplification using specific primers (A) will produce a unique product corresponding to the
sequence flanked by the primers and resolved as a unique band by gel electrophoresis (lane A). When low stringency conditions are applied, primers are likely
to anneal to multiple regions of the genome (B and C) and many sequences are co-amplified in a competitive and reproducible fashion, including the one for
which the primers are designed (lanes B and C). In this case, differences in copy number of the targeted sequence will be manifested as proportional changes
in the amount of its corresponding TAP-PCR product band as resolved by electrophoresis. Right panel corresponds to a 6% polyacrylamide (non-denaturing)
gel electrophoresis of c-myc amplification in the conditions described above. Lanes B and C contain the TAP-PCR products from a normal and its paired tumour
DNA respectiveiy. Gel was stained with ethidium bromide and colour inverted
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TAP-PCR
DLD1 SW480
1:0 31:1 15:1 7:1 3:1 0:1
1: 15:1 3:1 0:L
| | ~~~~~~1:0 15:1 3:1 0:1
Southem
Figure 2 c-myc allelic dosage of SW480 and DLD-1 cell line DNAs. (Top) Duplicated TAP-PCR analysis of pure and mixed DNAs (mixture proportions are
indicated at top) from these two cell lines. Solid arrow indicates the band identified as c-myc. Differences of intensity in this band are observed according to the
mixture proportions as shown in the densitometric analysis at right. For calculation purposes, the intensity of five arbitrary bands (indicated by empty arrows)
was monitored and used as reference. Densitogram is displayed for lanes marked with an asterisk. (Bottom) Southern blot hybridization analysis of the same
cell line DNAs with a c-myc probe. In addition to the 7.5-kb band, a fainter band of approximately 5 kb (not shown) was identified in the SW480 DNA, probably
corresponding to a genomic reorganization. The ethidium bromide staining of the digested genomic DNA before transfer is shown at left. TAP-PCR and
Southern blot analyses were performed as described in Material and methods
the third exon. The identity ofthe c-mvc band was checked by simul-
taneous electrophoresis ofthe TAP-PCR product with the product of
a conventional high-stringency PCR (annealing temperature, 65°C).
The co-migrating band was isolated, cloned and sequenced using
standard procedures (Peinado et al, 1992; Perucho et al, 1995).
Differences in the intensity ofbands between the tumour and its
paired normal tissue were ascertained by direct eye inspection of
the film. Relative increases in intensity of the c-myc band in the
tumour sample compared with its normal sample was considered a
symptom of gene amplification compared with the co-amplified
arbitrary bands. In addition, in order to have an objective measure-
ment of the magnitude of the change, films were scanned and
the intensity of bands quantified using Phoretix ID software
(Newcastle upon Tyne, UK). The intensity ofeach c-myc band was
divided by the sum of five arbitrary bands (Figure 2) in order to
have a relative measure when the overall intensity ofthe lanes was
not comparable. The ratio between normal tissue and tumour
tissue was used to determine the degree of amplification of the
c-myc gene in each case.
Method assessment
To test the sensitivity of this technique, duplicated serial dilutions
ofthe SW480 DNA in the DLD-1 DNA were analysed using TAP-
PCR and Southern blot hybridization. TAP-PCR was performed as
described earlier. For Southern blot analysis, 10 ,ug of DNA was
digested with Xba1 restriction endonuclease (New England
Biolabs, Beverly, MA, USA) and electrophoresed on a 0.7%
agarose gel. DNA denaturation and transfer to a blotting
membrane (Quiabrane, Quiagen, Santa Clarita, CA, USA) was
performed using standard procedures (Sambrook et al, 1989). The
filter was hybridized overnight with a c-myc probe labelled using
the random primer method (Prime-It, Stratagene, La Jolla, CA,
USA) with [t-32P]dCTP (Amersham). The probe was obtained by
cloning a PCR product generated with the same primers used for
TAP-PCR. The probe was sequenced to confirm its identity.
Statistical analysis
Statistical analysis was performed using the chi-square test,
ANOVA or unpaired t-test as appropriate. Contingency tables
were analysed using Fisher's exact test or the chi-square test.
Fifty-seven cases were included in the follow-up study (Table 1).
Given the limited size of our series with complete follow-up and
taking into account that five cases presented a late recurrence of
the disease (6 or 7 years after surgery), to determine the potential
application of c-myc amplification as a prognostic factor it was
considered more appropriate to use the disease-free survival
interval rather than the overall survival. Disease-free survival
distributions were calculated using the Kaplan-Meier method and
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analysed using the log-rank test. Multivariate analysis was
performed using the Cox proportional hazards model. Statistical
analysis was performed with SPSS software. All P-values are
estimated from two-sided statistical tests.
RESULTS
Method assessment
Sequencing of the TAP-PCR band co-migrating with the specific
PCR c-myc product (Figure 1) demonstrated its identity. Technique
sensitivity was determined by serial dilutions of the SW480 DNA
in the DLD-1 DNA and compared with southern blot hybridiza-
tion. Parallel results were obtained with both techniques (Figure
2). The maximum dilution ofSW480 in DLD-1 that appeared to be
distinguishable from uncontaminated DLD-1 was 1:31. As deter-
mined by densitometric analysis of the Southern blot hybridiza-
tion, the c-myc gene is about 13.5 ± 0.8 (mean ± s.d.)-fold
amplified in SW480 vs DLD-1, whereas using TAP-PCR it was
10.8 ± 0.7. This implies that a 1:31 dilution of SW480 DNA in
DLD-1 DNA will correspond to a 1.4 c-myc amplification for
DLD-1. As shown in Figure 2, TAP-PCR analysis is able to
resolve such tiny differences, indicating that the sensitivity of the
method is below a 1.5-fold amplification.
in Figure 3. The amplification ratio ranged from two- to fivefold
with an average of3.05 ± 1.02 (mean ± s.d.). Owing to the hetero-
geneous proportion of tumour cells in a given sample, tumours
have been classified as positive or negative for c-myc amplifica-
tion, taking into account that we have a minimal estimation of the
amplification ratio. Clinicopathological and molecular associa-
tions ofthe c-myc amplification are summarized in Table 2. Lymph
node-positive cases showed a higher incidence ofc-myc amplifica-
tion (47%) vs no lymph invasion (10%) (P = 0.0005). No differ-
ences were observed between Dukes' stages C and D. In tumours
containing a mutation in the p53 gene, c-myc was more often
amplified (P = 0.0484). No significant correlation was found with
other variables such as age, sex, race, tumour differentiation and
location and presence of mutations in the ras gene. None of the
eight tumours displaying microsatellite instability contained an
amplified c-myc; nevertheless, the differences did not reach statis-
tical significance.
Univariate survival analysis for the different parameters studied
(Table 3) indicated that advanced Dukes' stages and poor differen-
tiation were markers ofbad prognosis. Although cases with ampli-
fication of the c-myc gene also had a poorer disease-free survival
(log-rank, P = 0.0628), due to its strong association with more
advanced stages, it does not constitute an independent prognostic
factor as determined by multivariate Cox analysis (Table 3).
c-myc amplification in colorectal carcinomas
Taking into account the sensitivity of the technique and that our
tumour samples were likely to contain a significant proportion of
non-tumour cells, a minimal 1.5-fold increase in intensity in the
tumour compared with the normal was required to be considered
as an amplification. An intensity of the c-myc band in the tumour
tissue vs its paired normal tissue (> 1.5-fold) was observed in 18
out of 70 cases analysed (26%). An illustrative example is shown
'0>>,9 -t 45 83 125~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~................
°......
Figure 3 Duplicated TAP-PCR analysis of three normal tissue (N) and
tumour tissue (T) pairs. Numbers at top indicate case. Case 125 displays an
increase in the c-myc band (marked with an arrow) that after densitometric
analysis revealed a five-fold amplification in the tumour sample vs its paired
normal mucosa DNA. SW480 and DLD-1 cell lines were used as controls
Table 2 C-mycamplification in colorectal carcinomas
Parameter c-myc Significance
amplificationa P
Race
Black 3/16 (19) 0.5050
White 13/48 (19)
Sex
Female 6/20 (30) 0.6038
Male 12/50 (24)
Dukes' stage
A-B 4/40 (10) 0.0024
C 9/19 (47)
D 5/11 (45)
Lymph node invasion
Negative 4/40 (10) 0.0005
Positive 14/30 (47)
Location
Left 12/38 (31) 0.1220
Right 4/27 (15)
Differentiation
Well-Moderate 12/51 (23) 0.6639
Poor 3/10 (30)
ras mutation
Negative 14/46 (30) 0.2109
Positive 4/24 (17)
p53 mutation
Negative 3/24 (12) 0.0484
Positive 14/40 (35)
MMPb
Negative 18/62 (29) 0.0770
Positive 0/8 (0)
aNumbers indicate cases displaying c-mycamplification respect the total for
each category. Numbers in parentheses indicate percentages. bMicrosatellite
mutator phenotype.
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Table 3 Disease-free survival: univariate and multivariate analysis for
clinical pathological and genetic parameters
Univariate analysis
Prognostic
factor
Number of 5-year survival Log-rank
observations (percentage) P
Dukes' stage (Astler-Coller)
A-B
C
D
Degree of differentiation
Well-moderate
Poor
Location
Left
Right
ras mutation
Negative
Positive
p53 mutation
Negative
Positive
MMP
Negative
Positive
c-myc amplification
Negative
Positive
35
15
7
43
7
29
24
38
19
19
32
50
7
42
15
71.1
51.8
0
59.2
28.6
64.1
58.3
62.4
47.4
61.7
56.2
57.0
57.1
61.1
45.7
Cox multivariate
analysis
Step Variable Hazard ratio 95% Cl P
1 Dukes' stage (Astler-Coller)
A-B
C 1.8 0.7-4.3 0.1987
D 6.7 2.4-18.7 0.0003
2 c-myc amplification
Negative
Positive 1.2 0.5-2.8 0.6315
Overall survival analysis produced similar results (univariate
log-rank analysis, P = 0.0673; multivariate Cox analysis, hazard
ratio = 1.2, P = 0.7459).
DISCUSSION
Here, we report a variation of the AP-PCR fingerprinting tech-
nique by introducing a bias in the design of the primers towards
the amplification of a particular sequence. This variation makes
this technique suitable for the allelic dosage of specific genomic
sequences. A similar approach has been used to isolate cDNA
members of a genefamily (Stone et al, 1994) and toquantify colla-
genase expression in tumour cells (Vinyals et al, submitted).
The quality of the technique has been assessed by performing
reproducibility and sensitivity tests. Finally, it has been validated
by comparison with Southern blot hybridization analyses. The c-
myc copy number in the SW480 cell line was of the same order
when measured using Southern and TAP-PCR and in the same
range as previously described (Untawale and Blick, 1988). It can
be concluded that TAP-PCR is a reliable and sensitive method for
the allelic dosage of c-mvc. As the pattern is very reproducible
from individual to individual, concomitant analysis of the paired
normal mucosa is not absolutely necessary.
Nevertheless, in order to discard a polymorphic differential
PCR amplification ofone or many ofthe bands, it is highly recom-
mended to use normal tissue from the same patient as the control.
Owing to the intrinsic instability ofthe cancer cell genome, use of
multiple and diverse reference loci is an indispensable condition.
In consequence, one of the properties of AP-PCR, the random
chromosomal origin of the co-amplified bands (Peinado et al,
1992; Yasuda et al, 1996), is of special relevance to guarantee the
accuracy of the quantification.
The incidence of c-myc amplification in our series ofcolorectal
tumours is in the upper range (about 25%) of the data reported in
the literature, in agreement with Heerdt et al (1991) and Wang et al
(1994). As the amplifications we have seen are moderate (three-
fold in average), a lack of sufficient sensitivity may explain the
failure of other studies to detect such gains. Although not signifi-
cant, we have observed a lower incidence of c-myc amplification
in the right-side colon (Table 2). This is in agreement with a
previous study in which c-myc overexpression was more frequent
in the left colon (Rothberg et al, 1985). In fact, these authors have
already defined two pathways for sporadic colorectal tumours in
relationship to the familial syndromes. Tumours behaving like
hereditary non-polyposis colorectal cancer (HNPCC) were located
at the right side and did not overexpress c-myc, whereas tumours
behaving like familial polyposis coli were left sided and showed
c-mvc activation. In agreement with this observation, more recent
evidence has shown that a significant proportion of the right-side-
located tumours progress through a different molecular pathway
characterized by a DNA mismatch repair-deficient machinery
(Aaltonen et al, 1993; Ionov et al, 1993; Lothe et al, 1993;
Peltomaki et al, 1993; Thibodeau et al, 1993; Perucho et al, 1994).
These tumours do not show c-mvc amplification (Table 2) and, in
consequence, might be responsible for this trend.
Although there is a general agreement that c-myc amplification
is more frequent in more aggressive tumours, including colorectal,
gastric and lung (Heerdt et al, 1991; Yokota et al, 1986; Little et al,
1983; Shibuya et al, 1985), because of sample and technical
heterogeneity data are barely comparable. Tumours depicting c-
mvc amplification show a poorer disease-free and overall survival.
Unfortunately, the relevance of this association has a doubtful
application. The clear correlation with advanced Dukes' stages
indicates the dependency between both variables. This observation
also holds for overall survival. In consequence, assessment of c-
myc dosage status does not seem to be useful as aprognostic factor.
c-myc amplification is one of the multiple alterations that accu-
mulates during the tumour progression and its late appearance
suggests that it does not play a significant role in the transforma-
tion of the cell. Nevertheless, experimental evidence shows that
c-myc activation (which is not necessarily produced by gene
amplification) has a direct and important implication in multistage
carcinogenesis (Field and Spandidos, 1990). The apparent irrele-
vance, at clinical level, of c-mvc activation in colorectal cancer is
in a way expected and explained, at least in part, by its late
occurrence. It can be hypothesized that either the activation mech-
anism (amplification) is a late event, or the selective advantage
that it confers to the tumour cell is only displayed in late stages.
This is based on studies that indicate that c-myc activation induces
apoptosis (Evan et al, 1992). In consequence, for tumour cells,
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apoptosis overriding by activation/inactivation of other factors
(see Stewart, 1994 for review) would be a prerequisite before c-
invc amplification can occur. In fact, this hypothesis is supported
by our observation that c-myc amplification is associated with
mutations in the p53 gene (one of the inductors of apoptosis). In
this case, p53 inactivation [that presumably occurs in the
adenoma-carcinoma transition (Fearon and Vogelstein, 1990)]
will play a double role to facilitate c-myc activation, on one side by
inducing apoptosis abrogation (Yonish-Rouach et al, 1991; Shaw
et al, 1992) and on the other by overriding ofthe genomic stability
controls (Lane, 1992) that might prevent gene amplification
(Livingstone et al, 1992; Yin et al, 1992). The positive correlation
between c-myc activation and mutations in the p53 gene (Table 2)
supports this hypothesis.
Although we have stated gene 'amplification' as all copy number
increases observed at the c-myc level, this should be regarded with
caution, especially in view of the modest nature of such increases.
In addition, random screening of the cancer cell genome by AP-
PCR has revealed that many anonymous bands located in chromo-
some 8 (as it is the c-mvc gene) also display frequent gains, which
in some cases are associated with c-myc amplification (two out of
five) (unpublished data). This implies that the 'amplified' fragment
may include a wide chromosomal region. If this is the case, such
gains might affect a large region, if not all, of chromosome 8. This
argument has relevant implications for two reasons: first, the
number ofgenes displaying gains would be very high, and, in addi-
tion to c-mvc, many of these genes may affect tumour behaviour.
Second, the mechanism causing such imbalances is probably
different from the one producing small regional amplifications.
Precise characterization of the involved chromosomal fragment
should answer such questions. Interestingly, extensive AP-PCR
genome analysis of human cell lines carrying amplified c-mvc
genes showed that all ofthem displayed concurrent amplification of
other DNA fragments mapped to chromosome 8 (Okazaki et al,
1996). Okazaki et al (1996) hypothesize that these sequences are
part of an amplification unit that includes the c-mvc gene. The total
size ofthe amplified region in a small-cell lung carcinoma cell line
was estimated to be 7.5 Mb.
A possible inaccuracy in our results is the quantification of the
c-nvc copy number in tumour samples. Heterogeneous population
and contamination by normal cells might mask the real degree of
amplification. For this reason, we have only classified tumours as
positive or negative for c-mVc amplification, taking into account
that we have a minimal estimation of the amplification ratio.
Although the technique we have used is sensitive enough to detect
a relatively small amplification in a relatively small proportion of
the cells, it is obvious that this limitation will affect in a lower
grade more advanced tumours and consequently may mislead in
the interpretation of the results.
In summary, TAP-PCR appears to be an appropriate technique
to determine gene amplification. The low requirement of DNA
template and the simplicity of the technique indicates that it may
be especially useful in the analysis of small pieces that provide
insufficient amounts of material for analysis using other tech-
niques. Our study clearly demonstrates a significant incidence of
c-myc amplification in colorectal cancer and its association with
invasiveness. Owing to the complexity of c-mvc function in
cellular processes, further studies are required to elucidate the
participation of c-myc amplification in aetiogenesis and the conse-
quences that it may have for tumour progression.
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